title: Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series.
authors.affiliation: Istituto Oncologico Veneto - IRCCS, Padova, Italy. Electronic address: fable.zustovich@ioveneto.it.
authors.forename: Fable
authors.initials: F
authors.lastname: Zustovich
authors.affiliation: Istituto Oncologico Veneto - IRCCS, Padova, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ferro
authors.affiliation: Istituto Oncologico Veneto - IRCCS, Padova, Italy.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Farina
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000188:drug therapy / Q000556:secondary; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
keywords: Antiangiogenic; Cerebral; Kidney; Target therapy; VEGF